when were glp-1 agonists approved for weight loss Weight-loss drugs such as Ozempic in the headlines a lot in 2025 – and patent protections these drugs expire in some countries in 2026. In this edition of #PeriodicGraphics in @ History of GLP-1 Medications -

Cardiovascular Research Applications BPC-157 has shown promising results in cardiovascular research, with studies demonstrating cardioprotective effects, blood pressure regulation, and enhanced angiogenesis (new blood vessel formation) in damaged tissues

Sufferers experience lower energy levels, anxiety and depression

We demonstrate that melatonin-driven glutathione accumulation suppresses ILC2 effector cytokine production and ameliorates airway hyperreactivity and inflammation in multiple murine models of allergic airway disease

Exenatide Once Weekly Versus Placebo in Parkinsons Disease: A Randomised, Double-Blind, Placebo-Controlled Trial